Abstract
To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.
| Original language | English |
|---|---|
| Pages (from-to) | 1290-1298 |
| Number of pages | 9 |
| Journal | International Journal of Gynecological Cancer |
| Volume | 20 |
| Issue number | 7 |
| DOIs | |
| Publication status | Published - Oct 2010 |
Fingerprint
ASJC Scopus subject areas
- Medicine(all)
Cite this
Current academic clinical trials in ovarian cancer : Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009. / Trimble, Edward L.; Birrer, Michael J.; Hoskins, William J.; Marth, Christian; Petryshyn, Ray; Quinn, Michael; Thomas, Gillian M.; Kitchener, Henry C.; Gynecologic Cancer Intergroup National Cancer Institute Writing Committee, Cancer Intergroup National Cancer Institute Writing Committee; Aghajanian, Carol; Alberts, David S.; Armstrong, Deborah; Brown, Jubilee; Coleman, Robert L.; Colombo, Nicoletta; Eisenhauer, Elizabeth; Friedlander, Michael; Fujiwara, Keiichi; Hunsberger, Sally; Kaye, Stan; Ledermann, Jonathan A.; Lee, Susanna; Look, Katherine; Mannel, Robert; McNeish, Iain A.; Minasian, Lori; Oza, Amit; Paul, Jim; Poveda, Andres; Pujade-Lauraine, Eric; Schoenfeldt, Mason; Swart, Ann Marie; von Gruenigen, Vivian; Wenzel, Lari.
In: International Journal of Gynecological Cancer, Vol. 20, No. 7, 10.2010, p. 1290-1298.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Current academic clinical trials in ovarian cancer
T2 - Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.
AU - Trimble, Edward L.
AU - Birrer, Michael J.
AU - Hoskins, William J.
AU - Marth, Christian
AU - Petryshyn, Ray
AU - Quinn, Michael
AU - Thomas, Gillian M.
AU - Kitchener, Henry C.
AU - Gynecologic Cancer Intergroup National Cancer Institute Writing Committee, Cancer Intergroup National Cancer Institute Writing Committee
AU - Aghajanian, Carol
AU - Alberts, David S.
AU - Armstrong, Deborah
AU - Brown, Jubilee
AU - Coleman, Robert L.
AU - Colombo, Nicoletta
AU - Eisenhauer, Elizabeth
AU - Friedlander, Michael
AU - Fujiwara, Keiichi
AU - Hunsberger, Sally
AU - Kaye, Stan
AU - Ledermann, Jonathan A.
AU - Lee, Susanna
AU - Look, Katherine
AU - Mannel, Robert
AU - McNeish, Iain A.
AU - Minasian, Lori
AU - Oza, Amit
AU - Paul, Jim
AU - Poveda, Andres
AU - Pujade-Lauraine, Eric
AU - Schoenfeldt, Mason
AU - Swart, Ann Marie
AU - von Gruenigen, Vivian
AU - Wenzel, Lari
PY - 2010/10
Y1 - 2010/10
N2 - To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.
AB - To review the current status of large phase academic clinical trials for women with ovarian cancer, address cross-cutting issues, and identify promising areas for future collaboration. In May 2009, the Gynecologic Cancer Intergroup, which represents 19 Cooperative Groups conducting trials for women with gynecologic cancer, and the US National Cancer Institute convened a Clinical Trials Planning Meeting. The topics covered included the impact of new developments in cancer biology upon molecular targets and novel agents, pharmacogenomics, advances in imaging, the potential benefit of diet and exercise to reduce the risk of recurrence, academic partnership with industry, statistical considerations for phases 2 and 3 trials, trial end points, and symptom benefit and health-related quality-of-life issues. The clinical trials discussed spanned the spectrum of ovarian cancer from initial diagnosis, staging, and cytoreductive surgery to consolidation chemotherapy, and treatment of recurrent disease. Ongoing and effective collaboration with industry, government, and patients aims to ensure that the most important scientific questions can be answered rapidly. We encourage women with ovarian cancer and their oncologists to consider participation in the academic clinical trials conducted by the member groups of the Gynecologic Cancer Intergroup.
UR - http://www.scopus.com/inward/record.url?scp=79952667176&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79952667176&partnerID=8YFLogxK
U2 - 10.1111/IGC.0b013e3181ee1c01
DO - 10.1111/IGC.0b013e3181ee1c01
M3 - Article
VL - 20
SP - 1290
EP - 1298
JO - International Journal of Gynecological Cancer
JF - International Journal of Gynecological Cancer
SN - 1048-891X
IS - 7
ER -